Kyverna Therapeutics Inc.

3.02
0.02 (0.67%)
At close: Feb 10, 2025, 3:59 PM
3.04
0.78%
After-hours Feb 10, 2025, 06:55 PM EST
undefined%
Bid 2.97
Market Cap 130.16M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.96
PE Ratio (ttm) -1.02
Forward PE n/a
Analyst Buy
Ask 3.04
Volume 182,677
Avg. Volume (20D) 386,846
Open 3.00
Previous Close 3.00
Day's Range 2.97 - 3.06
52-Week Range 2.97 - 30.60
Beta undefined

About KYTX

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2024
Employees 96
Stock Exchange NASDAQ
Ticker Symbol KYTX

Analyst Forecast

According to 5 analyst ratings, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 696.02% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts
7 months ago
+1.23%
Kyverna Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
7 months ago
Kyverna Therapeutics shares are trading higher after the company announced KYV-101 received FDA IND clearance for the treatment of patients with treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 trial.